Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Lisa Rydén"'
Preexisting Somatic Mutations of Estrogen Receptor Alpha (ESR1) in Early-Stage Primary Breast Cancer
Autor:
Malin, Dahlgren, Anthony M, George, Christian, Brueffer, Sergii, Gladchuk, Yilun, Chen, Johan, Vallon-Christersson, Cecilia, Hegardt, Jari, Häkkinen, Lisa, Rydén, Martin, Malmberg, Christer, Larsson, Sofia K, Gruvberger-Saal, Anna, Ehinger, Niklas, Loman, Åke, Borg, Lao H, Saal
Publikováno v:
JNCI Cancer Spectrum
Background More than three-quarters of primary breast cancers are positive for estrogen receptor alpha (ER; encoded by the gene ESR1), the most important factor for directing anti-estrogenic endocrine therapy (ET). Recently, mutations in ESR1 were id
Autor:
Olle Stål, Svanheiður Rafnsdóttir, Éamon Hughes, Göran Landberg, Karoline Berger, Maria Ekholm, Ylva Magnusson, Lisa Rydén, Sara Rhost
Publikováno v:
BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
Background The growth factor progranulin has been implicated in numerous biological processes such as wound healing, inflammation and progressive tumorigenesis. Both progranulin and its receptor sortilin are known to be highly expressed in subgroups
Autor:
Cecilia Hegardt, Lao H. Saal, Henrik Lindman, Anna Ehinger, Niklas Loman, Lisa Rydén, Jari Häkkinen, Johan Staaf, Johan Vallon-Christersson, Tobias Sjöblom, Åke Borg, Martin Malmberg, Helena Olofsson, Fredrik Wärnberg, Christer Larsson
Publikováno v:
Scientific Reports
Scientific Reports, Vol 9, Iss 1, Pp 1-16 (2019)
Scientific Reports, Vol 9, Iss 1, Pp 1-16 (2019)
Multigene expression signatures provide a molecular subdivision of early breast cancer associated with patient outcome. A gap remains in the validation of such signatures in clinical treatment groups of patients within population-based cohorts of uns
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::701bec1df2c5b7dfded55b4d9db66239
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-393727
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-393727
Autor:
Bo Nordenskjöld, Mårten Fernö, Lisa Rydén, Olle Stål, Maria Ekholm, Pär-Ola Bendahl, South Swedish
Aims: The primary aim was to compare 2 years of adjuvant tamoxifen versus no systemic treatment in premenopausal patients with oestrogen receptor (ER) epositive tumours, regarding breast cancerefree interval (BCFi) and distant recurrenceefree interva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35af7af165c2d0af235f814f1ddd6f38
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-155552
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-155552
Publikováno v:
European Journal of Cancer; 51(16), pp 2304-2313 (2015)
Aim A contralateral breast cancer (CBC) is today treated as an independent primary tumour, although recent data suggest risk and prognosis of CBC to be influenced by characteristics of and treatment given for the first tumour (BC1). We hereby investi
Publikováno v:
Cell Cycle. 10:956-962
The retinoblastoma tumor suppressor (RB) is important for retaining cell cycle control and loss of RB function is commonly observed in various malignancies. Experimental and animal studies have shown that RB knockdown in ER+ (estrogen receptor) cell
Publikováno v:
World Journal of Surgery. 34:1434-1441
Prognostic and treatment-predictive biomarkers in primary breast cancer are routinely analyzed in the primary tumor, whereas metastatic tumor cells in lymph node metastases are not characterized. The present study aimed to define the concordance betw
Publikováno v:
Breast Cancer Research and Treatment. 120:491-498
Triple-negative breast cancer (TNB) has poor prognosis and moreover patients with TNB do not benefit from established targeted drugs with endocrine therapy or trastuzumab. The aim of the study was to analyze the prevalence of candidate biomarkers in
Autor:
Donal J. Brennan, Åsa Kronblad, William M. Gallagher, Sallyann L. O'Brien, Göran Landberg, Karin Jirström, Robert C. Millikan, Lisa Rydén, Michael J. Duffy
Publikováno v:
Clinical Cancer Research. 12:6421-6431
Purpose: Hypoxia in breast cancer is associated with poor prognosis and down-regulation of the estrogen receptor. Carbonic anhydrase IX (CA IX) is a hypoxia-inducible gene that has been associated with poor outcome in many epithelial cancers. Previou
Publikováno v:
International Journal of Cancer; 118(10), pp 2609-2616 (2006)
Hypoxia is common in many solid tumours, including breast cancer. Hypoxia triggers the expression of hypoxia inducible factor-1 alpha (HIF-1 alpha), and HIF-1 alpha has been associated with an impaired prognosis in breast cancer and down-regulation o